含猪抗淋巴细胞球蛋白或兔抗胸腺细胞球蛋白的体内T细胞清除方案在单倍体造血干细胞移植中预防急性移植物抗宿主病的有效性
本研究比较猪抗淋巴细胞球蛋白(p-ALG)与兔抗胸腺细胞球蛋白(r-ATG)在单倍体造血干细胞移植(haplo-HSCT)中的临床疗效。p-ALG 75 mg/kg组、p-ALG 90 mg/kg组和r-ATG 7.5 mg/kg组的中性粒细胞和血小板植入率分别为100%、93.6%、94.4%和100%、93.6%、90.3%。p-ALG 75 mg/kg组巨细胞病毒感染率显著低于其他两组。p-ALG(75 mg/kg)可能作为r-ATG的合适替代。
要点
- p-ALG 75 mg/kg组中性粒细胞和血小板植入率分别为100%和93.6%,与r-ATG 7.5 mg/kg组(94.4%和90.3%)相似。
- p-ALG 75 mg/kg组巨细胞病毒感染率显著低于p-ALG 90 mg/kg组和r-ATG 7.5 mg/kg组。
- p-ALG(75 mg/kg)可能作为r-ATG(7.5 mg/kg)在haplo-HSCT预处理方案中的合适替代。
核心结论
- p-ALG(75 mg/kg)与r-ATG(7.5 mg/kg)在haplo-HSCT中疗效和安全性相似,p-ALG(75 mg/kg)可能作为r-ATG的合适替代。
研究设计与样本
- 比较p-ALG与r-ATG在haplo-HSCT中临床疗效的研究,p-ALG 75 mg/kg组n=57,p-ALG 90 mg/kg组n=49,r-ATG 7.5 mg/kg组n=72。
主要发现
- 中性粒细胞植入率分别为100%、93.6%和94.4%;血小板植入率分别为100%、93.6%和90.3%(p-ALG 75 mg/kg、p-ALG 90 mg/kg、r-ATG组)。
- 中性粒细胞植入中位时间分别为11、12和12天(p=0.032);血小板植入中位时间分别为13、14和13天(p=0.013)。
- II-IV度急性GVHD发生率分别为16.7%、12.5%和13.3%(p=0.817);慢性GVHD累积发生率分别为14.7%、12.1%和19.5%。
- p-ALG 75 mg/kg组巨细胞病毒感染率显著低于其他两组。
- 2年复发累积发生率和2年总生存率相似(p=0.901,p=0.497)。
临床怎么用
- 作者认为p-ALG(75 mg/kg)可能作为r-ATG在haplo-HSCT预处理方案中的合适替代。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To compare the clinical efficacy of porcine anti-lymphocyte globulin (p-ALG) and rabbit anti-thymocyte globulin (r-ATG) in the treatment of haematological malignancies using haploidentical haematopoietic stem cell transplantation (haplo-HSCT), this study was conducted. The incidences of neutrophil and platelet engraftment, respectively, were 100%, 93.6% and 94.4%; 100%, 93.6% and 90.3% in p-ALG 75 mg/kg (n = 57), p-ALG 90 mg/kg (n = 49), and r-ATG 7.5 mg/kg (n = 72). The median time to neutrophil engraftment and platelet engraftment were 11, 12 and 12 days (p = 0.032); 13, 14 and 13 days (p = 0.013), respectively. The incidence of grades II-IV acute graft-versus-host disease and cumulative incidence of chronic graft-versus-host disease were 16.7% versus 12.5% versus 13.3% (p = 0.817) and 14.7% versus 12.1% versus 19.5% in p-ALG 75 mg/kg, p-ALG 90 mg/kg and r-ATG groups. Notably, the cytomegalovirus infection rate in the p-ALG 75 mg/kg group was significantly lower than the other two groups. The cumulative incidence of 2-year relapse and 2-year overall survival rates were similar (p = 0.901, p = 0.497). The lower dose of p-ALG (75 mg/kg) had a similar efficacy and safety profile compared with r-ATG (7.5 mg/kg) in the setting of haplo-HSCT. Therefore, p-ALG (75 mg/kg) may be an appropriate alternative to r-ATG in the conditioning regimen of haplo-HSCT.
引用
- Xu Z, Zhou X, Zhao X, et al. Effectiveness of in vivo T-cell-depleted regimen containing porcine anti-lymphocyte globulin or rabbit anti-thymocyte globulin in preventing acute graft-versus-host disease after haploidentical haematopoietic stem cell transplantation. Br J Haematol. 2023. PMID: 37984846. doi:10.1111/bjh.19205
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。